Compound Detail

CHEMBL459

METHYLDOPA

💊 Approved Drug

Enter ChEMBL ID:

Free Research Context This compound will appear in recent viewed items on the research home for this browser.

Research home View demo workspace

💊 Approved Drug

C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O

ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID	CHEMBL459
Name	METHYLDOPA
Phase	Approved
Structure Type	MOL
InChI Key	CJCSPKMFHVPWAR-JTQLQIEISA-N
Therapeutic	✓ Yes

Known Names

(-)-.alpha.-methyldopa (s)-(-)-.alpha.-methyldopa .alpha.-methyl-l-dopa Aldomet Alpha-methyldopa Anhydrous methyldopa BAYER-1440L Dopamet Dopegyt J9.247I L-.alpha.-methyldopa Lederdopa +16 more

Targets

Activities

Assay Types

PK Parameters

Publications

Known Names

Indications

Mechanisms

Molecular Properties

211.2

MW (Da)

0.44

ALogP

HBA

HBD

103.8

PSA (Å²)

0.54

QED

Ro5 Violations

Rot. Bonds

Drug Information

Molecule Type	Small molecule
First Approval	1962
Availability	Prescription
Chirality	Single Enantiomer

Routes of Administration

Oral

Flags

Natural Product

USAN Stem	-dopa
USAN Year	1962

Extended Properties

Molecular Formula	C10H13NO4
MW	211.22
Aromatic Rings	1
Heavy Atoms	15
NP-Likeness	1.09

Mechanism of Action

Mechanism	Action Type	Target	Direct	Efficacy
Adrenergic receptor alpha-2 agonist	AGONIST	Adrenergic receptor alpha-2	✓	✓

Indications

Hypertension Diabetes Mellitus, Type 1 Pre-Eclampsia

ATC Classification

C02AB01

methyldopa (levorotatory)

Level 1: CARDIOVASCULAR SYSTEM

Level 2: ANTIHYPERTENSIVES

Activity Summary

IC50 5 meas. best 5.67

Target Activity Profile

Target	Type	Best pChEMBL	Mean pChEMBL	Best (nM)	# Data
Polyunsaturated fatty acid lipoxygenase ALOX15 CHEMBL4358	IC50	5.67	5.67	2126.0	1
Lysine-specific demethylase 4E CHEMBL1293226	IC50	5.52	5.52	3000.0	1
Tyrosine-protein kinase Fyn CHEMBL1841	IC50	5.29	5.29	5176.0	1
Epidermal growth factor receptor CHEMBL203	IC50	5.28	5.28	5228.0	1

Pharmacokinetic Data

Parameter	Value	Units	Species
AUC	58300.0	ng.hr.mL-1	Canis lupus familiaris
AUC	32600.0	ng.hr.mL-1	-
CL	3.5	mL.min-1.kg-1	Homo sapiens
CL	1.4	mL.min-1.kg-1	Homo sapiens
CL	3.5	mL.min-1.kg-1	Homo sapiens
CL	3.5	mL.min-1.kg-1	Homo sapiens
F	26.0	%	Homo sapiens
Fu	0.85	-	Homo sapiens
Fu	0.85	-	Homo sapiens
MRT	3.3	hr	Homo sapiens
T1/2	3.6	hr	-
T1/2	3.4	hr	-
T1/2	5.9	hr	Homo sapiens

Activity Data Samples

Top measurements by pChEMBL value

Target	Type	Rel.	Value	Units	pChEMBL	Assay	PubMed
Polyunsaturated fatty acid lipoxygenase ALOX15	IC50	=	2126.0	nM	5.67	DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid)	-
Lysine-specific demethylase 4E	IC50	=	3000.0	nM	5.52	Inhibition of N-terminal His-6-tagged human JMJD2E (1 to 337 residues) expressed...	-
Tyrosine-protein kinase Fyn	IC50	=	5176.0	nM	5.29	DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:...	-
Epidermal growth factor receptor	IC50	=	5228.0	nM	5.28	DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: ...	-

Literature References

PubMed	DOI	Target Context	# Activities
-	10.6019/CHEMBL3885861	Rattus norvegicus	1403
-	10.6019/CHEMBL3885881	Rattus norvegicus	492
16472241	10.2174/1570163043334794	Hepatotoxicity	18
22194678	10.1371/journal.pcbi.1002310	Hepatotoxicity	14
15646539	10.1016/s0399-8320(04)95062-2	Unchecked	11
20070106	10.1021/jm901371v	Homo sapiens	8
15646539	10.1016/s0399-8320(04)95062-2	NON-PROTEIN TARGET	8
915896	10.1021/jm00221a005	Rattus norvegicus	8
9836611	10.1021/jm9810102	No relevant target	7
6737413	10.1021/jm00372a002	ADMET	6
7452699	10.1021/jm00186a030	Rattus norvegicus	5
7452694	10.1021/jm00186a021	Rattus norvegicus	5
-	10.6019/CHEMBL4495565	SARS-CoV-2	4
18426954	10.1124/dmd.108.020479	ADMET	4
6737413	10.1021/jm00372a002	Canis familiaris	3
20014752	10.1021/tx900326k	Hepatotoxicity	3
20373811	10.1021/jm901846t	No relevant target	3
19445515	10.1021/jm900403j	Homo sapiens	2
1246045	10.1021/jm00223a040	Rattus norvegicus	2
22931300	10.1021/tx300075j	Liver microsomes	2

Data from ChEMBL 36 via Core Engine